



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Kukolj & Pause) Confirm. No.: 9062
Serial No.: 10/789,355) Art Unit: 1648
Filed: February 27, 2004) Examiner: Li, Bao Q.
For: Self-Replicating RNA Molecule from Hepatitis C Virus
Docket No.: 13/083-3-D2

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE


Sir:

This is in response to a communication received from the Examiner in charge of the subject application, which communication was mailed on October 18, 2005.

The communication mailed October 18th comprised a restriction requirement. Applicants, through their attorney, hereby elect for prosecution the invention designated as Group I, claims 1 and 3 through 6 drawn to a HCV polynucleotide comprising one substitution mutation. Additionally, as requested by the Examiner, applicants elect as species G2042C. However, it is respectfully requested that the second mutation G2042R be included in the search, since such mutation is at the same position.

The election is without traverse.

Respectfully submitted,



Mary-Ellen M. Devlin
Attorney for Applicants
Reg. No. 27,928


Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road, P.O. Box 368
Ridgefield, CT 06877
Tel: (203) 798-4866

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

on November 16, 2005.



Mary-Ellen M. Devlin, Reg. No. 27,928